Novo Nordisk Has The Largest One Day Decline Since December 20th
Novo Nordisk (NOVOB.DK) is down more than 5.5% today following the release of Phase 3 clinical trial results for its new obesity drug, CagriSema. The company reported positive study outcomes, showing that patients with type 2 diabetes and obesity experienced a 15.7% reduction in body weight after 68 weeks of treatment, compared to a 3.1% weight loss in the placebo group. However, prior expectations (before the December 20 report) anticipated a 25% weight reduction.
Novo Nordisk’s stock is currently trading at this year’s support level around 550 DKK, a zone defined by the consolidation phase before the strong rally in 2023, driven by positive results from its Wegovy obesity drug. Source: xStation
The company stated that the study confirmed high drug efficacy, and it plans to submit the drug for regulatory approval in Q1 2026.
Despite the positive trial results, investors reacted with a significant sell-off. Today’s drop marks the biggest one-day decline since the December 20 selloff, which occurred after the company published initial CagriSema trial results. Earlier company expectations projected a 25% weight reduction, while December’s data suggested around 20% weight loss.
Another factor that may have disappointed investors is the proportion of patients opting for the maximum drug dose, which was approximately 61%. In this trial, patients had the option to self-adjust their dosage levels.
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
